Market Cap 69.92M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 89,400
Avg Vol 317,844
Day's Range N/A - N/A
Shares Out 6.88M
Stochastic %K 85%
Beta 0.52
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
dcpanda
dcpanda Oct. 4 at 6:45 PM
$CVM golden cross in play. Prepare for big moves next week 🍻
0 · Reply
CashNCarry
CashNCarry Oct. 4 at 3:56 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:40 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:39 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:39 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Latest News on CVM
CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 5 weeks ago

CEL-SCI Announces Closing of $10 Million Public Offering


CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 5 weeks ago

CEL-SCI Announces Pricing of $10 Million Public Offering


CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 5 weeks ago

CEL-SCI Announces Proposed Public Offering


CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 7 weeks ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results


CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 4 months ago

CEL-SCI Announces Closing of Public Offering


CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 4 months ago

CEL-SCI Announces Pricing of Public Offering


CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 4 months ago

CEL-SCI Announces Combination of Common Stock


CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 5 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results


CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 7 months ago

CEL-SCI Announces Closing of $2.5 Million Offering


CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 7 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering


CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 8 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial


CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 9 months ago

CEL-SCI Announces Closing of $5 Million Offering


CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 9 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering


CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 10 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock


CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering


CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering


CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board


CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors


CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders


dcpanda
dcpanda Oct. 4 at 6:45 PM
$CVM golden cross in play. Prepare for big moves next week 🍻
0 · Reply
CashNCarry
CashNCarry Oct. 4 at 3:56 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:40 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:39 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:39 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:38 PM
0 · Reply
Thebullrun
Thebullrun Oct. 4 at 2:37 PM
0 · Reply
MitchOnX
MitchOnX Oct. 4 at 12:49 PM
$CVM $CVM Cel-Sci Corp. - 60 Second Analysis - October 4, 2025 #CVM #CELSCI #... https://youtu.be/s7_Vv0eFDEY?si=lVZfXMxWQhDDonzJ via @YouTube
0 · Reply
cruiser24
cruiser24 Oct. 4 at 11:20 AM
$CVM Abstract The randomized controlled pivotal phase 3 study evaluated efficacy and safety of neoadjuvant complex biologic, Leukocyte Interleukin Injection (LI), administered for 3 consecutive weeks pre-surgery, in treatment naïve resectable locally advanced primary squamous cell carcinoma of oral cavity and soft palate. Randomization 3:1:3 to LI+/-CIZ (cyclophosphamide, indomethacin, and zinc)+SOC, or SOC (standard of care) alone. LI-treated patients received 400 IU (as interleukin-2 equivalent; 200 IU peritumorally, 200 IU perilymphatically) sequentially, daily 5 days/week for 3 weeks before surgery. All subjects were to receive SOC. Post-surgery, patients with low risk for recurrence were to receive radiotherapy, while those with high risk received concurrent chemoradiotherapy. Median follow-up was 56 months. There were 923 ITT (Intent-to-Treat) subjects (380 ITT low-risk and 467 ITT high-risk). Pre-surgery objective early response (45 objective early responders; 5 complete resp
3 · Reply
cruiser24
cruiser24 Oct. 4 at 11:18 AM
0 · Reply
ImmxBeliever
ImmxBeliever Oct. 4 at 1:26 AM
$CVM A real apple doesn’t fall far from the tree story. Two utter morons Cheers
0 · Reply
ImmxBeliever
ImmxBeliever Oct. 3 at 10:12 PM
$CVM Why do you need two accounts Dr? @DrAndreG @andreg_26 This clown has been around for at least 5 years. He was a sushi fan boi! Cheers
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:39 PM
$CVM $CDT $CNEY $BON Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
Thebullrun
Thebullrun Oct. 3 at 5:43 PM
$CVM let’s rock into the weekend!! Awesome!
1 · Reply
cruiser24
cruiser24 Oct. 3 at 3:09 PM
$CVM BULLISH AS WE all know news can be released today, next week, or tomorrow. I’m sure Dallah-pharma will have a say on when news is released. I am personally betting on after hours but hat is not by knowledge but only wishes.
1 · Reply
dcpanda
dcpanda Oct. 3 at 3:02 PM
$CVM News next week? Give it a 50/50 chance. All the talk is over. 🍻
1 · Reply
cruiser24
cruiser24 Oct. 3 at 2:22 PM
$CVM $CVM BULLISH I appreciate all your comments on my Rawhide theme song. Here is what’s on my mind today. I feel like moving on. I'm getting older So I'll keep it straight It hurts to let go, but it Hurts more to stay I'm movin' on I'm movin' on, hey I'm movin' Hey, hey, hey, hey, hey I know my rear view Can't compare to What God will do with my life And I am forgetting What's behind me I have finally decided I'll be Movin' on I'm movin' on (alright) I'm movin on
0 · Reply
cruiser24
cruiser24 Oct. 3 at 2:01 PM
$CVM $CVM BULLISH Sentiment 53 Finally back in the green.
0 · Reply